Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase

Jun 29 2018

• By Sten Stovall

Listen to this article

Cablivi is first therapeutic to receive positive CHMP opinion for treating acquired thrombotic thrombocytopenic purpura, a rare blood disorder.

Thrombotic — CHMP Backing Keeps Cablivi On EU Launch Track For aTTP • Source: Shutterstock

The logic behind Sanofi's purchase of Ablynx NV this year has had an important validation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) which has recommended approval of Cablivi (caplacizumab) in Europe for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder.

Cablivi was developed by Ablynx, now a Sanofi company. It is a first-in-class anti-von Willebrand factor (vWF) Nanobody for the...

More from Blood and Clotting

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone
Feb 04 2026
• By Urtė Fultinavičiūtė
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod
Aug 15 2024
• By Alaric DeArment
US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.
Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III
Jul 24 2024
• By Jessica Merrill
The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.
Abecma Or Bust: 2seventy Sells Final Research Program To Novo
Jun 27 2024
• By Jessica Merrill
2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.